Group 6 Copy 80
0
    Please wait...

    About This Project

    OncoSynergy, Inc.
    The Ebola outbreak in west Africa has been declared a global emergency by the WHO with over 1,000 victims and no approved therapies. OncoSynergy is developing a readily manufactured experimental cancer drug, OS2966, which coincidentally targets the receptor hijacked by ebola to infect cells. This project aims to demonstrate that OS2966 inhibits ebola infection of human cells thus providing the impetus for expediting OS2966 for treatment of ebola.
    Blast off!

    Browse Other Projects on Experiment

    Related Projects

    Low cost snake antivenom for Asia, Africa and South America

    Death by snake venom in India, Africa, and South America are substantial. Traditional antidotes are prohibitively...

    Using Gene Therapy to Target and Treat Cancers

    Non-coding RNAs regulate levels of gene expression in cells, meaning that we now have a unique tool that...

    Backer Badge Funded

    A biology project funded by 47 people